Natural Products Insider is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
HomeBusiness ResourcesBusiness OperationsLabs/TestingChromaDex Announces Top Line Results of its Second Human Clinical Trial

ChromaDex Announces Top Line Results of its Second Human Clinical Trial

<p>ChromaDex Corp. (NASDAQ:CDXC announced today that the initial results of its second human clinical study of NIAGEN<sup>&reg;</sup> nicotinamide riboside chloride (NR) have confirmed NR significantly and sustainably raises the co-enzyme nicotinamide adenine dinucleotide (NAD+) in 140 healthy human volunteers over 8-weeks.</p>
TAGS: Healthy Living Ingredients Business Resources
Hide comments
account-default-image
user not logged in

More information about text formats

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish
Related
USP Feature Image 1021.png
Paid Content
Meeting retailer requirements with the USP Verified Mark – infographic
Oct 04, 2021
IITA guest Len Monheit
What we learned at SupplySide East
Sep 08, 2021
probiotics.jpg
Considerations for probiotic storage, handling and packaging
Aug 09, 2021
cbd testing.jpg
CBD, delta-8 THC and other cannabinoids’ place in sport and drug testing
Jul 28, 2021